ENGN net incomeQ3 2026-$32.50M
ENGN net income was -$32.50M in fiscal Q3 2026 (ended Jul 31, 2026), compared with -$28.99M a year earlier. For the full fiscal 2025 it was -$117.30M, compared with -$55.14M in fiscal 2024.
enGene Therapeutics Inc. (ENGN) financials
For the twelve months ended Jul 31, 2026, enGene Therapeutics Inc. reported -$130.36M of net income.
- Net income, TTM
- -$130.36M
- Free cash flow, TTM
- -$104.00M
- EPS, diluted, TTM
- $2.43
- Cash
- $41.02M
- Market cap
- $118.6M
FY2022FY2025
FY2022FY2025
ENGN revenue and earnings growth
ENGN EPSQ3 2026-$0.47
- FY YoY
- +56.8%
ENGN diluted EPS was -$0.47 in fiscal Q3 2026 (ended Jul 31, 2026), compared with -$0.57 a year earlier. For the full fiscal 2025 it was $2.29, up 56.8% from fiscal 2024.
ENGN free cash flowQ3 2026-$18.95M
ENGN free cash flow was -$18.95M in fiscal Q3 2026 (ended Jul 31, 2026), compared with -$26.34M a year earlier. For the full fiscal 2025 it was -$100.72M, compared with -$49.21M in fiscal 2024.
Income statement
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 |
|---|---|---|---|---|
| Research and development | $94.48M | $38.31M | $16.46M | $15.47M |
| Selling, general and admin | $28.68M | $23.98M | $9.60M | $3.96M |
| Operating income | -$123.17M | -$62.30M | -$26.06M | -$19.43M |
| Interest expense | $2.99M | $2.80M | $4.95M | $1.42M |
| Pre-tax income | -$117.30M | -$55.16M | -$99.90M | -$24.44M |
| Income tax | $0 | -$19.0K | $17.0K | $22.0K |
| Net income | -$117.30M | -$55.14M | -$99.92M | -$24.46M |
| EPS, basic | $2.29 | $1.46 | $151.22 | $44.30 |
| EPS, diluted | $2.29 | $1.46 | $151.22 | $44.30 |
| Diluted shares | 51.1M | 37.8M | 692,609 | 655,153 |
Balance sheet
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $50.15M | $173.00M | $81.52M | $20.43M |
| Short-term investments | $143.58M | $65.33M | - | - |
| Current assets | $201.39M | $247.36M | $85.44M | $22.58M |
| Total assets | $221.47M | $311.17M | $86.96M | $23.91M |
| Current liabilities | $31.98M | $14.66M | $5.26M | $5.10M |
| Total liabilities | $53.76M | $38.56M | $14.47M | $47.41M |
| Shareholders' equity | $167.71M | $272.61M | $72.49M | -$76.61M |
Cash flow
| Line item | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$99.24M | -$48.28M | -$24.74M | -$17.59M |
| Capital expenditures | $1.49M | $925.0K | $318.0K | $153.0K |
| Free cash flow | -$100.72M | -$49.21M | -$25.06M | -$17.75M |
| Investing cash flow | -$25.14M | -$125.95M | -$318.0K | -$153.0K |
| Financing cash flow | $1.52M | $265.72M | $86.15M | $27.97M |
| Dividends paid | - | - | $0 | - |
| Stock-based compensation | $9.65M | $5.32M | $3.45M | $116.0K |
| Depreciation and amortization | $500.0K | $300.0K | $200.0K | $200.0K |
Key ratios
Income statement
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $20.09M | $22.20M | $22.25M | $31.72M | $22.57M | $20.21M | $19.97M | $11.27M | $11.55M | $9.86M | $5.64M | $5.67M |
| Selling, general and admin | $13.92M | $9.77M | $8.93M | $7.76M | $7.37M | $6.92M | $6.64M | $6.18M | $5.21M | $7.46M | $5.13M | $4.77M |
| Operating income | -$34.01M | -$31.97M | -$31.18M | -$39.48M | -$29.95M | -$27.12M | -$26.61M | -$17.45M | -$16.76M | -$17.31M | -$10.77M | -$10.44M |
| Interest expense | $843.0K | $745.0K | $732.0K | $750.0K | $758.0K | $734.0K | $752.0K | $756.0K | $751.0K | $728.0K | $563.0K | $1.16M |
| Pre-tax income | -$32.50M | -$30.23M | -$29.75M | -$38.38M | -$28.75M | -$25.57M | -$24.60M | -$15.28M | -$14.18M | -$14.96M | -$10.74M | -$82.48M |
| Income tax | $0 | $0 | $0 | -$497.0K | $239.0K | $240.0K | $18.0K | $19.0K | -$29.0K | $21.0K | -$30.0K | $17.0K |
| Net income | -$32.50M | -$30.23M | -$29.75M | -$37.88M | -$28.99M | -$25.82M | -$24.62M | -$15.30M | -$14.15M | -$14.98M | -$10.71M | -$82.50M |
| EPS, basic | -$0.47 | -$0.43 | $0.44 | $2.89 | -$0.57 | -$0.51 | $0.48 | - | $0.32 | $0.38 | $0.46 | $120.08 |
| EPS, diluted | -$0.47 | -$0.43 | $0.44 | $2.89 | -$0.57 | -$0.51 | $0.48 | - | $0.32 | $0.38 | $0.46 | $120.08 |
| Diluted shares | 69.7M | 69.7M | 67.3M | - | 51.1M | 51.0M | 51.0M | - | 44.2M | 39.4M | 23.2M | - |
Balance sheet
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $41.02M | $29.83M | $36.61M | $50.15M | $32.62M | $57.55M | $62.35M | $173.00M | $257.68M | $264.81M | $85.65M | $81.52M |
| Short-term investments | $225.29M | $228.64M | $239.34M | $143.58M | $169.29M | $159.85M | $151.47M | $65.33M | - | - | - | - |
| Current assets | $277.90M | $270.00M | $289.22M | $201.39M | $211.31M | $227.97M | $222.32M | $247.36M | $262.69M | $269.61M | $89.58M | $85.44M |
| Total assets | $288.32M | $307.52M | $337.11M | $221.47M | $245.55M | $266.65M | $285.93M | $311.17M | $266.88M | $273.53M | $93.42M | $86.96M |
| Current liabilities | $27.21M | $21.48M | $24.61M | $31.98M | $20.44M | $18.00M | $12.96M | $14.66M | $13.46M | $6.30M | $6.91M | $5.26M |
| Total liabilities | $58.03M | $52.36M | $55.57M | $53.76M | $44.88M | $39.36M | $35.98M | $38.56M | $36.55M | $30.56M | $31.04M | $14.47M |
| Shareholders' equity | $230.29M | $255.17M | $281.55M | $167.71M | $200.67M | $227.29M | $249.95M | $272.61M | $230.33M | $242.97M | $62.38M | $72.49M |
Cash flow
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.95M | -$30.50M | -$28.90M | -$24.96M | -$25.63M | -$22.95M | -$25.70M | -$19.57M | -$7.18M | -$14.16M | -$7.37M | -$6.78M |
| Capital expenditures | $0 | $98.0K | $153.0K | $437.0K | $704.0K | $45.0K | $299.0K | $238.0K | $2.0K | $179.0K | $506.0K | $138.0K |
| Free cash flow | -$18.95M | -$30.60M | -$29.06M | -$25.40M | -$26.34M | -$22.99M | -$26.00M | -$19.81M | -$7.18M | -$14.34M | -$7.88M | -$6.91M |
| Investing cash flow | $30.12M | $23.64M | -$126.30M | $40.50M | $1.38M | $17.95M | -$84.96M | -$125.27M | -$2.0K | -$179.0K | -$506.0K | -$138.0K |
| Financing cash flow | $23.0K | $74.0K | $141.66M | $1.99M | -$667.0K | $199.0K | $1.0K | $60.16M | $51.0K | $193.50M | $12.00M | $50.84M |
| Stock-based compensation | $7.81M | $4.14M | $2.80M | $2.61M | $2.58M | $2.65M | $1.81M | $1.66M | $1.46M | $1.92M | $291.0K | $3.35M |
| Depreciation and amortization | $100.0K | $200.0K | $189.0K | $200.0K | $100.0K | $100.0K | $102.0K | $100.0K | $100.0K | $100.0K | $80.0K | $74.0K |
Key ratios
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS growth, YoY | - | - | -8.3% | - | - | - | - | - | - | - | - | - |
| Current ratio | 10.21 | 12.57 | 11.75 | 6.30 | 10.34 | 12.66 | 17.16 | 16.87 | 19.52 | 42.80 | 12.97 | 16.25 |
Source: XBRL data enGene Therapeutics Inc. files with the SEC, latest filing dated Sep 8, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ENGN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ENGN | - | - | -$130.36M | - | $118.6M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
ENGN FAQ
6 questionsIs ENGN profitable?
No. enGene Therapeutics Inc. reported a net loss of $130.36M for the twelve months ended Jul 31, 2026.How much cash and debt does ENGN have?
enGene Therapeutics Inc. reported $41.02M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ENGN free cash flow?
enGene Therapeutics Inc. generated -$104.00M of free cash flow for the twelve months ended Jul 31, 2026, which is operating cash flow of -$103.31M less capital expenditures.What is ENGN earnings per share?
Diluted earnings per share were $2.43 for the twelve months ended Jul 31, 2026, from SEC filings, restated for any stock split those filings show.When did ENGN last report financial results?
The latest statements here come from enGene Therapeutics Inc.'s 10-Q filed on Sep 8, 2026, covering the period ended Jul 31, 2026.Where does this ENGN financial data come from?
Quantisnow builds these statements from the structured XBRL data enGene Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.